NO960341L - Rekombinant C140-reseptor og dens agonister og antagonister - Google Patents

Rekombinant C140-reseptor og dens agonister og antagonister

Info

Publication number
NO960341L
NO960341L NO960341A NO960341A NO960341L NO 960341 L NO960341 L NO 960341L NO 960341 A NO960341 A NO 960341A NO 960341 A NO960341 A NO 960341A NO 960341 L NO960341 L NO 960341L
Authority
NO
Norway
Prior art keywords
receptor
antagonists
availability
agonists
recombinant
Prior art date
Application number
NO960341A
Other languages
English (en)
Other versions
NO960341D0 (no
Inventor
Robert M Scarborough
Johan Sundelin
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Publication of NO960341D0 publication Critical patent/NO960341D0/no
Publication of NO960341L publication Critical patent/NO960341L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

DNA som koder for C14 0-celleoverflate-reseptoren er blitt klonet og sekvensert. Tilgjengeligheten av dette DNAet tillater rekombinant fremstilling av C140-reseptoren, som kan dannes på celle- eller oocytt-overflater og er anvendelig i testsystemer både for deteksjonen av substanser som påvirker dens aktivitet, omfattende agonister og antagonister. Videre muliggjør avsløringen av strukturen til C14 0-reseptoren utfo-rmning av agonist- og antagonist-forbindelser som er anven-delige i disse testene. Tilgjengeligheten av C140-reseptoren tillater også produksjon av antistoffer som er spesifikt immunoreaktive med reseptoren per se, eller med spesifikke regioner derav.
NO960341A 1993-07-26 1996-01-26 Rekombinant C140-reseptor og dens agonister og antagonister NO960341L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/097,938 US5629174A (en) 1993-07-26 1993-07-26 Recombinant C140 receptor
PCT/US1994/008536 WO1995003318A1 (en) 1993-07-26 1994-07-26 Recombinant c140 receptor and its agonists and antagonists

Publications (2)

Publication Number Publication Date
NO960341D0 NO960341D0 (no) 1996-01-26
NO960341L true NO960341L (no) 1996-03-26

Family

ID=22265852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960341A NO960341L (no) 1993-07-26 1996-01-26 Rekombinant C140-reseptor og dens agonister og antagonister

Country Status (12)

Country Link
US (1) US5629174A (no)
EP (1) EP0804452B1 (no)
JP (1) JPH09503906A (no)
KR (1) KR960703939A (no)
CN (1) CN1057118C (no)
AT (1) ATE205502T1 (no)
AU (1) AU701677B2 (no)
CA (1) CA2168232A1 (no)
DE (1) DE69428292T2 (no)
NO (1) NO960341L (no)
NZ (1) NZ271516A (no)
WO (1) WO1995003318A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716789A (en) * 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor
US6602978B1 (en) * 1994-10-28 2003-08-05 Chrysalis Biotechnology Synthetic peptide neutrophil cell chemotactic agents
US20020032314A1 (en) * 1994-10-28 2002-03-14 Chrysalis Biotechnology, Inc. Synthetic peptide neutrophil cell chemotactic agents
NZ334998A (en) * 1995-01-25 2000-11-24 Cor Therapeutics Inc Use of an agonist or antagonist for inhibiting the expression of a C140 receptor
US5892014A (en) * 1996-10-30 1999-04-06 The Regents Of The University Of California DNA encoding a protease-activated receptor 3
US6737252B2 (en) 1997-07-25 2004-05-18 Schering Corporation 7 transmembrane receptor family member BLRX
US20030013155A1 (en) * 1998-08-20 2003-01-16 Millennium Pharmaceuticals, Inc. 14400 receptor, a novel G-protein coupled receptor
JP3677421B2 (ja) * 1999-12-27 2005-08-03 扶桑薬品工業株式会社 涙液分泌促進組成物
KR100436441B1 (ko) * 2001-10-11 2004-06-16 한국화장품주식회사 지속성 립스틱 조성물
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019646A (en) * 1987-08-25 1991-05-28 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5128254A (en) * 1989-11-01 1992-07-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cdna encoding the long isoform of the d2 dopamine receptor
AU701822B2 (en) * 1993-07-26 1999-02-04 Millennium Pharmaceuticals, Inc. Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor

Also Published As

Publication number Publication date
JPH09503906A (ja) 1997-04-22
ATE205502T1 (de) 2001-09-15
AU7516794A (en) 1995-02-20
CA2168232A1 (en) 1995-02-02
EP0804452B1 (en) 2001-09-12
NZ271516A (en) 1997-01-29
EP0804452A4 (en) 1998-08-12
CN1057118C (zh) 2000-10-04
DE69428292T2 (de) 2002-06-27
NO960341D0 (no) 1996-01-26
EP0804452A1 (en) 1997-11-05
DE69428292D1 (de) 2001-10-18
WO1995003318A1 (en) 1995-02-02
AU701677B2 (en) 1999-02-04
US5629174A (en) 1997-05-13
KR960703939A (ko) 1996-08-31
CN1131950A (zh) 1996-09-25

Similar Documents

Publication Publication Date Title
EP1378524A3 (en) Recombinant thrombin receptor antibodies and their use
NO960341L (no) Rekombinant C140-reseptor og dens agonister og antagonister
Lichtshtein et al. Muscarinic receptor regulation of NG108-15 adenylate cyclase: requirement for Na+ and GTP.
WO1998010068A3 (en) Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
DE69011329T2 (de) Pdgf-alpha-rezeptor.
ATE203566T1 (de) Protein-g-gekoppelte glutaminsäure-rezeptoren
Van Breemen et al. Calcium fluxes in isolated rabbit aorta and guinea pig tenia coli.
CA2309903A1 (en) Nucleic acid sequences encoding capsaicin receptor
Winslow et al. Enzymatic regulation of mast cell activation and secretion by adenylate cyclase and cyclic AMP-dependent protein kinases.
ATE362983T1 (de) Menschlicher lysophosphatidsäure rezeptor und dessen verwendung
Schmidt et al. Evidence for a D1 dopamine receptor in the salivary glands of Amblyomma americanum (L.).
WO2000028032A3 (en) Human cell surface receptor proteins
WO1999035106A3 (en) Mammalian edg-7 receptor homologs
Kratzsch et al. Measurement of serum exon 3-retaining growth hormone-binding protein in children and adolescents by radioimmunoassay
WO1999055901A3 (en) Screening assay for identifying human purinoreceptor ligands
Johnson et al. Identification and topography of substrates for protein carboxyl methyltransferase in synaptic membrane and myelin‐enriched fractions of bovine and rat brain
Bymaster et al. Arachidonic acid release in cell lines transfected with muscarinic receptors: a simple functional assay to determine response of agonists
BR9506511A (pt) Processo e composiçao para prevenir ou reduzir a severidade de psoriase processo para evitar proliferaçao das células e processo para diagnosticar ou predizir a susceptibilidade á psoriase e vetor
Majeed et al. Serotonergic regulation of the brain and gut beta-endorphin and dynorphin content in the rat.
Zhu et al. Alterations in Activities of Protein Phosphatases PP1 and PP2A in and B Lymphocytes of Autoimmune MRL/MpJ-lpr/lpr Mice
DE69131289D1 (de) Polypeptide mit einer aktivität des menschlichen dopaminergischen rezeptors, deren kodierende nukleinsäuresequenzen und verwendung dieser polypeptide
Doggrell Further analysis of the inhibitory effects of dihydroergotamine, cyproheptadine and ketanserin on the responses of the rat aorta to 5-hydroxytryptamine.
Yang et al. EGF receptor in human Chang liver and hepatoma HepG2 cells.
Schlesinger et al. The nature and function of T-cell antigens.
KANAMORI et al. Involvement of β1-adrenergic receptors in regulation of the phosphorylation state of rat parotid gland proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application